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PURPOSE. To explore the molecular mechanisms by which
the C–C chemokine receptor type 3 (CCR3) and chemokine
(C–C motif) ligand 11 (CCL11) regulate choroidal endothe-
lial cell (CEC) migration and the interactions with the vas-
cular endothelial growth factor (VEGF) signaling pathway.
METHODS. Human retinal sections from young and aged donor
normal eyes were immunolabeled. By real-time PCR, CCR3
mRNA was measured in retinal pigmented epithelium (RPE)/
choroids obtained from young and aged human donor eyes and
in cultured CECs exposed to hydrogen peroxide. CCR3 ligand
and CCL11- or VEGF-stimulated CEC migration was also mea-
sured in the presence of the CCR3 inhibitor or control using
fluorescence microscopy. Activation of Rac1, phosphorylated
Akt as a readout for phosphoinositol 3-kinase signaling, and
VEGFR2 activation were measured in CECs incubated with
CCL11, VEGF, or combined CCL11/VEGF.
RESULTS. CCR3 was expressed to a greater level in older
compared with that in younger human retinas or RPE/
choroids. Ligand-activated CCR3 increased CEC migration,
which was inhibited by the CCR3 inhibitor. Rac1 activity,
p-Akt, and p-VEGFR2 were significantly increased in CECs
incubated with CCL11. The CCR3 inhibitor prevented VEGF-
induced CEC migration and Rac1 activation in CECs. Rac1
activity was additively increased in CECs treated with CCL11
and VEGF compared with that in cells with CCL11 or VEGF
treatment alone. Ligand-activated CCR3 caused VEGFR2
phosphorylation and coimmunoprecipitation of VEGFR2
and CCR3.
CONCLUSIONS. Activated CCR3 promotes CEC migration and
Rac1 activation and causes an association with and activation
of VEGFR2. Cross-talk between CCR3 and VEGF signaling ex-
ists and may be important in choroidal neovascularization in
human age-related macular degeneration. (Invest Ophthalmol
Vis Sci. 2011;52:8271–8277) DOI:10.1167/iovs.11-8230
Neovascular age-related macular degeneration (AMD) ac-counts for 80% of legal blindness in a rapidly growing
percentage of the U.S. population, that is, those older than 60
years of age.1 Outcomes have improved with anti–vascular
endothelial growth factor (VEGF) treatment,2 but visual acuity
still improves in only 40% of cases, and repeated intraocular
injections pose serious ocular risks, including endophthalmitis
and retinal detachment.3 Also, treatment benefit is lost after
repeated intravitreal injections of VEGF antibody,4 raising a
concern of potential retinal toxicity or recurrent choroidal
neovascularization (CNV) caused by compensatory mecha-
nisms through altered regulation of angiogenic and inhibitory
growth factors or other signaling.5–8 Thus, considering path-
ways besides the VEGF pathway is important in the develop-
ment of therapies for neovascular AMD. The G-protein–cou-
pled receptor (GPCR), C–C chemokine receptor 3 (CCR3), was
reported to be important in neovascular AMD.9 Additional
evidence supports its role in CNV.10 However, a recent study
reported that CCR3 was not important in CNV development
when using a CNV gelatinous protein mixture (Matrigel; BD
Biosciences, Franklin Lakes, NJ) model.11 Therefore, further
study regarding the potential role of CCR3 in AMD is needed.
AMD is a complex disease, influenced by environmental and
genetic factors. In this study, we focused on the effects of
environmental stresses associated with AMD on CCR3 expres-
sion in choroidal endothelial cells (CECs). We studied the
mechanisms whereby CCR3 signaling activates CECs to mi-
grate, a key event before the development of vision-threatening
sensory retinal CNV. We obtained data from human donor eyes
and used cultured human CECs and retinal pigmented epithe-
lium (RPE). We also explored the hypothesis that CCR3 and
VEGF work synergistically in triggering downstream signaling
pathways. We report that the CCR3 ligand, chemokine (C–C
motif) ligand 11 (CCL11), activates VEGF receptor 2 to trigger
activation of the small GTPase Rac1, which we previously
reported is necessary for CEC transmigration of the RPE.12–14
METHODS
Cell Culture
CECs were isolated from young donor eyes obtained from the North
Carolina Eye Bank as previously reported.15 Enriched condition (EC)
phenotype was confirmed by labeling of EC markers (CD31, vwF, and
VE-cadherin), and passages 2 through 5 were used in experiments.
CECs were maintained in endothelial growth medium-2 (EGM-2; Lonza,
Walkersville, MD) with 10% fetal bovine serum (FBS). ARPE-19 cells
were obtained from American Type Culture Collection (Rockville, MD)
and grown in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F-12;
Invitrogen, Carlsbad, CA) plus 10% FBS and penicillin–streptomycin.
Cells below passage 18 were used for experiments.
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CEC Migration Assay
CCL11 and VEGF (R&D Systems, Minneapolis, MN) were reconstituted
in 0.1% BSA and then mixed with gelatinous protein mixture extract
(Matrigel; BD Biosciences) diluted 1:1 with serum-free endothelial
basal media (EBM-2; Lonza). Controls were PBS in 0.1% BSA mixed in
gelatinous protein mixture extract. A small molecule CCR3 inhibitor
that specifically prevents ligand binding to CCR3 with an IC50 of 28
nM (US 2010/0273795 A1; a gift of Axikin Pharmaceuticals, San Diego,
CA) was dissolved in dimethyl sulfoxide and used at concentrations
from 1 to 1000 nM. EBM-2 (500 L) was added to each well of a 24-well
plate followed by a 6.5-mm-diameter insert (8-m pores; Transwell;
Corning, Inc., Corning, NY). Human CECs in EBM-2 were prestained
with cell-labeling solution (Vybrant DiO; Invitrogen, Carlsbad, CA) for
30 minutes at 37°C and seeded into the inserts at 50,000 cells per 200
L of serum-free EBM-2 media. The plates were allowed to incubate for
24 hours at 37°C, 5% CO2. The migrated cells were imaged with a
culture microscope and microscope digital camera (Olympus CK40
and Olympus DP71, respectively; both Olympus America, Inc., Center
Valley, PA).
Rac-1 Activity Assay
Human CECs were cultured in EGM-2 containing 10% FBS. Before
starting the assay, cells were serum starved with basal medium EBM2
(Lonza) for at least 2 hours. Cells were stimulated for designated times
with CCL11 (10 ng/mL) or/and VEGF (20 ng/mL) and PBS was used as
control. Equal amounts of lysates (500 g) were incubated for 30
minutes at 4°C, with rotation with glutathione S-transferase–p21-acti-
vated kinase 1 p21 binding domain agarose beads (Millipore, Te-
mecula, CA) to pull down active guanosine triphosphate (GTP)–bound
Rac-1. The samples were subsequently analyzed for bound Rac-1 by
Western blot analysis using an anti–Rac-1 antibody (BD Transduction
Laboratories, San Jose, CA).
Phospho-Akt and Phospho-STAT3 Assays
Human primary CECs were grown in 6-well plates. After starving in
serum-free EBM-2, cells were incubated with CCL11 (10 ng/mL), VEGF
(20 ng/mL), or both for 30 minutes. Cells were lysed in radioimmuno-
precipitation assay (RIPA) buffer to probe phospho-Akt and total AKT
using antibodies for p-Akt and Akt1 or for phospho-STAT3 and total
STAT3 (Cell Signaling Technology, Danvers, MA).
Phospho-VEGFR2 by Immunoprecipitation
Human CECs were seeded into 6-well plates. After 2 hours of starving
in serum-free EBM-2, cells were treated with CCL11 (10 ng/mL) for 0,
15, 30, or 60 minutes. Cells were harvested in RIPA buffer and cell
lysates were probed by immunoprecipitation and Western blot analysis
to detect phospho-VEGFR2 using antibodies to VEGFR2 (Santa Cruz
Biotechnology, Santa Cruz, CA) and phospho-tyrosine (BD Transduc-
tion Laboratories). As a positive control, phospho-VEGFR2 was deter-
mined in cells after a 15-minute incubation with VEGF (20 ng/mL).
Immunolabeling with CCR3
Human retinal paraffin sections of eyes from a 91-year-old male donor,
obtained through the Georgia Eye Bank, were deparaffinized and an
antigen-retrieval step was performed with antigen-retrieval solution
(Dako North America, Inc., Carpinteria, CA) before immunostaining.
Human retinal cryosections from an eye of a 25-year-old male donor
was obtained from the Utah Lions Eye Bank. For immunolabeling in
CECs, human CECs grown on uncoated coverslips were fixed with 4%
paraformaldehyde for 20 minutes, then rinsed in PBS. Cells and retinal
sections were incubated in 2% normal goat serum in PBS/0.5% Triton
X-100 for 1 hour, to block nonspecific binding of the primary antibody.
Sections were incubated with rabbit anti-CCR3 (1:50 dilution; Santa
Cruz Biotechnology) overnight at 4°C. After three washes in PBS,
sections were incubated for 1 hour with a 1:500 dilution of dye-
conjugated goat anti-rabbit secondary antibody (Alexa Fluor 488; Invit-
rogen, Carlsbad, CA) for CCR3. The sections were rinsed in PBS,
stained with the nuclear dye 4,6-diamidino-2-phenindole, and
mounted in a water-soluble, nonfluorescing compound (Fluoro-
mount-G; SouthernBiotech, Birmingham, AL). Images were captured
with an inverted microscope (Olympus 1X81, Tokyo, Japan) and dig-
itally stored for analysis.
RNA Isolation and Real-Time PCR
Cells were removed from culture medium and washed with cold PBS.
Total RNA was extracted by use of a single-step RNA isolation reagent
(Tri-Reagent; Sigma-Aldrich, St. Louis, MO). RNA was quantified by use
of a microvolume instrument (NanoDrop; Thermo Fisher Scientific,
Inc., Waltham, MA). cDNA was generated using a commercial kit
(High-Capacity cDNA Archive Kit; Applied Biosystems, Foster City,
CA). RT-PCR was performed on a gene-sequence detector instrument
(ABI Prism 7500; Applied Biosystems) using probes (TaqMan probes;
Applied Biosystems) to human CCR3 and -actin genes and primers to
CCL11, CCL24, and CCL26 (SYBR Green qPCR Master Mix; Clontech,
Mountain View, CA). Expression levels for all genes were normalized
to the mean value of internal control human -actin. Sequences for the
primers (SYBR Green) were as follows: human CCL11: Forward 5-
AGAAGAAGTGGGTGCAGGATTCCA-3, Reverse 5-TTAGGCAACACT-
CAGGCTCTGGTT-3; human CCL24: Forward 5-AGAAGAAGTGGGT-
GCAGGATTCCA-3, Reverse 5-TTAGGCAACACTCAGGCTCTGGTT-3;
human CCL26: Forward 5-AGAAGAAGTGGGTGCAGGATTCCA-3, Re-
verse 5-TTAGGCAACACTCAGGCTCTGGTT-3.
Statistical Analyses
Significant differences between groups were determined by ANOVA
with post-hoc protected t-tests, as indicated for specific experiments in
the figure legends. All experiments had an n  3 to n  6. Cell
migration experiments and Rac1 activity assays were repeated three
times. A minimum value of P  0.05 was considered statistically
significant.
RESULTS
CCR3 Expression in Human Retina and
RPE/Choroids from Young and Aged Donors
Age is the leading factor associated with increased risk of
AMD.16 We previously reported that all VEGF splice variants
were significantly increased in RPE from eyes of donors older
than 70 years of age compared with donors between 20 and 40
years of age.14 Because we found that CCR3 was important in
human neovascular AMD,9 we predicted that eyes from donors
of increased age would show greater expression of CCR3 than
that of eyes from younger donors. Figures 1A and 1B showed
that immunolabeling with CCR3 appeared qualitatively greater
in the retina from a 91-year-old donor’s eye compared with
(Fig. 1B) that from a 25-year-old donor’s (Fig. 1A). We then
measured CCR3 mRNA in RPE/choroids from young and old
donor eyes (n  3 from each) by quantitative real-time PCR.
CCR3 mRNA was significantly increased in RPE/choroids from
aged versus young donors (Fig. 1C). We next determined the
expression level of CCR3 in cultured CECs and RPE cells. We
found that CCR3 mRNA was highly expressed in CECs, with a
nearly 10-fold increase compared with RPE (Fig. 2A). This
finding was supported by positive CCR3 labeling in cultured
CECs (Fig. 2B), whereas there was no CCR3 label in cultured
RPE (data not shown).
CCR3 Expression Increased in Cultured CECs by
AMD-Related Stresses
Evidence supports both exogenous and endogenous reactive
oxidative species (ROS) as factors involved in pathologic steps
in AMD.12,17–20 We therefore determined the effect of H2O2 on
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CCR3 expression level in CECs. We previously reported that
600 M H2O2 caused a significant and selective upregulation of
the VEGF189 splice variant in RPE.
14 However, in CECs, there
was no change in the expression levels of VEGF splice variants,
VEGF121, VEGF165, and VEGF189.
14 To determine the effect of
H2O2 on CCR3 expression in CECs, a dose–response experi-
ment was performed with H2O2 at 100, 300, or 600 M
concentrations. After incubation for 24 hours, CCR3 expres-
sion in CECs was found to be increased 4-fold from control at
the 300 M concentration (Fig. 2C). In cultured RPE, H2O2
exposure also caused a significant increase in CCR3 mRNA
compared with control, although the expression levels re-
mained 10-fold less than that of CCR3 (data not shown).
When RPE were exposed to 300 M H2O2, there was a
significant 15-fold increase in expression of all three CCR3
ligands (CCl11, CCl24, and CCl26; Fig. 2D), whereas CEC
expression of all three ligands was unchanged from control
after exposure to 300 M H2O2 (data not shown). There-
fore, age and oxidative stress appeared to upregulate CCR3
in both CECs and RPE, and induce increased CCR3 ligand
production only in RPE cells.
CEC Migration Is Increased by CCR3 Ligand
We were then interested in the effects of CCR3 signaling on
CEC migration. We measured CEC migration after stimulation
with the CCR3 ligand, CCL11. We found that at a dose of 10
ng/mL, CCL11 induced migration of CECs with a twofold
increase over control. This ligand-induced CEC migration was
significantly inhibited by a CCR3 inhibitor in a dose-dependent
manner, consistent with previous findings9 (Fig. 3).
FIGURE 1. CCR3 expression in hu-
man retinal sections and RPE/cho-
roids. Representative immunostain-
ing of CCR3 in human retinal
sections from 25-year-old (A) and 91-
year-old (B) donors using anti-CCR3
antibody (magnification, 40). (C)
The expression of CCR3 mRNA was
measured by real-time PCR in RPE/
choroid from aged and young do-
nors. *P  0.05 vs. young (n  3
individual donor eyes for each
group).
FIGURE 2. CCR3 expression in
CECs and RPE cells increased by
AMD-related stresses. CCR3 expres-
sion in CECs and RPE cells (A, C) and
its ligands in RPE cells (D) were mea-
sured by real-time PCR. (A) Cultured
human CECs and RPE cells. ***P 
0.001 vs. RPE (n  6). (B) CCR3
immunostaining in cultured CECs.
(C) Human CECs were exposed to
H2O2 at different doses (100, 300,
and 600 M) for 6 hours. *P  0.05
vs. 0 M H2O2 (n  6). (D) Human
ARPE-19 cells were incubated with
300 M H2O2 for 6 hours. **P  0.01
vs. control (n  6).
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Effect of CCR3 on EC Signaling Pathways
Several signaling pathways can lead to CEC migration. The
Janus kinase/signaling transducer and activator of transcription
pathway can mediate EC and other cell migration through
phosphorylation of STAT3.21 We reported that soluble VEGF
activated phosphoinositol 3-kinase (PI 3-kinase) signaling and
VEGF receptor 2 (VEGFR2), and both were important in CEC
transmigration of the RPE13,15 by mediating the activation of
the small GTPase, Rac1, in CECs.12–14 As shown in Figure 4A,
after stimulation with CCL11 (10 ng/mL) for 30 minutes, we
found a significant activation of PI 3-kinase determined by
increased p-Akt. However, when VEGF was used to stimulate
p-Akt, we did not find activation at the same time points as
CCL11 stimulated p-Akt, nor did we find p-STAT3 increased at
the time points tested in CECs after stimulation with CCL11 or
VEGF (data not shown). We next measured Rac1 activity in
CECs incubated with CCL11 for different times. At a dose of 10
ng/mL, CCL11 significantly induced Rac1 activity at 30 minutes
and the effect was sustained through 60 minutes (Fig. 4B). This
was similar to the time course of VEGF-stimulated Rac1 activa-
tion we previously observed in CECs.12 We then determined
whether CCL11-induced Rac1 activation was mediated through
the CCR3 receptor. CECs were pretreated with the small mol-
ecule CCR3 inhibitor for 30 minutes before stimulation with
CCL11 and assayed for Rac1 activity. Rac1 activation induced
by CCL11 was significantly inhibited by the CCR3 inhibitor at
100 nM and, at the 1 M dose, the CCR3 inhibitor totally
blocked CCL11-stimulated Rac1 activation (Fig. 4C).
Cross-talk between CCR3 and VEGF Signaling
Results in Figure 4 indicate that ligand-activated CCR3 induced
CEC migration through PI 3-kinase/Rac1 signaling. Our previ-
FIGURE 3. CCR3 ligand CCl11 promotes CEC migration. The number
of migrated CECs toward gelatinous protein mixture extract (Matrigel;
BD Biosciences) mixed with 10 ng/mL CCL11 or control was measured
after incubation with control or CCR3 inhibitor at different doses (1
nM, 10 nM, 100 nM, 1 M, and 10 M) for 24 hours. Migrated CECs
toward gelatinous protein mixture extract without CCL11 were used
as a control (No-CCL11). Overall one-way ANOVA P  0.0001; post-
hoc Newman-Keuls multiple comparison testing: ***P  0.001 vs.
No-CCL11, ##P  0.01, ###P  0.001 vs. CCL11 alone (n  9).
FIGURE 4. CCL11 stimulates PI 3-kinase and Rac1 activation via CCR3. Rac1 activation was measured by pull-down assays in CECs. (A) p-Akt-1 and
total Akt-1 were measured in CECs incubated with CCL11 (10 ng/mL) for 30 minutes as a readout for PI 3-kinase activity. *P  0.05 vs. control (n 
3, representative experiment). (B) CECs were incubated with 10 ng/mL CCL11 for 0, 5, 15, 30, and 60 minutes or treated with 20 ng/mL VEGF
for 60 minutes as a positive control. *P  0.05 vs. 0 min of CCL11 treatment (n  6). (C) CECs were pretreated with CCR3 inhibitor at two doses
(100 nM and 1 M) for 30 minutes, and then cells were exposed to 10 ng/mL CCL11 for 60 minutes. Overall one-way ANOVA P  0.0001; post-hoc
Newman-Keuls multiple comparison testing: ***P  0.001 vs. control; #P  0.05 and ###P  0.001 vs. CCL11 alone (n  6).
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ous studies also showed that VEGF activated PI 3-kinase and
Rac1 to cause CEC transmigration of the RPE.13,15 We then
determined whether there was cross-talk between the CCR3
and VEGF signaling pathways to mediate CEC activation. CEC
migration toward VEGF165 was measured in the presence of
different concentrations of the CCR3 inhibitor. We found that
the CCR3 inhibitor caused a dose-dependent decrease in VEGF-
induced CEC migration that was significant at all doses mea-
sured (Fig. 5A). We then determined whether the CCR3 inhib-
itor was able to prevent VEGF-induced Rac1 activation. CECs
were pretreated with the CCR3 inhibitor for 30 minutes and
exposed to VEGF or control for 1 hour. Rac1 was measured in
cells lysates using pull-down assays. VEGF-induced Rac1
activation was significantly inhibited by the CCR3 inhibitor
(Fig. 5B).
One mechanism whereby cross-talk between signaling path-
ways can occur is through colocalization of receptors. We
performed coimmunoprecipitation assays for VEGFR2 and
CCR3 in CECs incubated with CCL11 (10 ng/mL) and VEGF (20
ng/mL) for 30 minutes. We found that CCR3 bound to VEGFR2
in response to combined CCL11 and VEGF treatment (Fig. 6A).
When CECs were stimulated with CCL11 alone, p-VEGFR2 was
significantly increased compared with control at 15 minutes,
with a maximum at 60 minutes, which was similar to the effect
obtained by VEGF stimulation alone (Fig. 6B). This finding
provided evidence that CCL11-induced stimulation of CCR3
can also induce the phosphorylation of VEGFR2. We then
determined if the interaction between CCR3 and VEGFR2 af-
fected downstream Rac1 activation. After a 1-hour stimulation
with VEGF, CCL11, or both ligands together, we found CCL11
and VEGF each caused a significant increase in Rac1 activation,
and exposure to both ligands led to an additive increase in
Rac1 activity (Fig. 6C).
DISCUSSION
In this study, we found that the chemokine receptor CCR3 was
significantly expressed in CECs in conditions associated with
increased risk of AMD, that is, older age and oxidative stress.
We also found that the mRNA for ligands of CCR3 (CCL11,
CCL24, and CCL26) were expressed in RPE and were increased
in response to H2O2 challenge. CCR3 labeling was greater in
aged human retinas compared with younger donor eyes such
as reported in specimens of human neovascular AMD.9 How-
ever, Li et al.11 reported that CCR3 was not involved in CNV
caused when gelatinous protein mixture extract (Matrigel; BD
Biosciences) was injected through the sclera into the subretinal
space to cause choroidal neovascularization. There may be
several reasons for this. CCR3 may be expressed under certain
conditions: increased age or oxidative stress, both known fac-
tors associated with advanced AMD. We found supporting
evidence of this in our cell culture studies. Previously we found
that laser to induce CNV in mouse retinas caused increased
generation of ROS through activated NADPH oxidase.12 In this
report, we found that ROS increased CCR3 expression in CECs
and CCR3 ligand expression in RPE. It is not clear whether
retinal ROS generation is affected in the in vivo gelatinous
protein mixture extract (Matrigel; BD Biosciences) CNV assay.
In this study, we explored potential mechanisms whereby
CCR3 signaling would lead to neovascular AMD, focusing on
FIGURE 5. CCR3 inhibitor blocks VEGF-induced CEC migration and Rac1 activation. (A) Migrated CECs
toward gelatinous protein mixture extract (Matrigel; BD Biosciences) mixed with 20 ng/mL VEGF or
control were measured after cells were incubated with control or CCR3 inhibitor at different doses (1 nM,
10 nM, 100 nM, 1 M, and 10 M) for 24 hours. Migrated CECs toward gelatinous protein mixture extract
without VEGF were used as a negative control and neutralizing VEGF antibody as positive controls. Overall
one-way ANOVA P  0.0001; post-hoc Newman-Keuls multiple comparison testing: ***P  0.001 vs.
Non-VEGF, ##P  0.01 vs. VEGF alone. #P  0.05, ###P  0.001 vs. CCL11 alone (n  6). (B) Rac1 activity
was measured by pulldown assay in CECs pretreated with CCR3 inhibitor for 30 minutes and then
exposed to 20 ng/mL VEGF or control for 1 hour. Overall one-way ANOVA P  0.0001; post-hoc
Newman-Keuls multiple comparison testing: ***P  0.001 and **P  0.01 vs. control; ###P  0.001 vs.
VEGF (n  6).
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CEC activation and migration. In agreement with our earlier
report,9 the CCR3 ligand, CCL11, mediated CEC migration and
the activation of Rac1, and this was inhibited by a specific
CCR3 inhibitor that blocked binding of the ligand to the re-
ceptor. We had previously reported that Rac1 is essential to
CEC transmigration of the RPE.12–14 Rac1 is a small GTPase of
the Rho family that is activated by guanine nucleotide ex-
change factors. In the GTP-bound activated state, Rac1 can
modulate cell behavior by binding to effector proteins. It is
returned to the inactive state by GTPase-activating proteins
(GAPs) that promote hydrolysis of bound GTP to guanosine
diphosphate (GDP).22 Rac122,23 has a number of cell functions,
many related to regulation of the actin cytoskeleton, such as
control over cell motility and migration.24–26 Rac1 is also a
subunit of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, which generates ROS that can then act as a
second messenger, as in angiogenesis.27 We found that VEGF
activated Rac1 and mediated NADPH oxidase-generated ROS in
CECs and in CNV after laser injury.12 From the data in this
report, Rac1 also appear to be activated downstream of CCL11-
stimulated CCR3 signaling.
We found PI 3-kinase was activated in CECs stimulated with
CCL11. We had previously reported that PI 3-kinase was in-
volved in soluble VEGF-mediated CEC transmigration as an
upstream regulator for Rac1.13 However, unlike VEGF and
CCL11, which had an additive effect in activating Rac1, we did
not find a synergistic effect between VEGF and p-Akt.
CCR3, as a GPCR, historically has been studied for its role in
eosinophil chemotaxis and, more recently, in angiogenesis.9,28
In this report, we studied the interaction between VEGF and
CCR3 signaling pathways in mediating CEC migration toward
the chemokine CCL11. There are several reasons to study
potential cross-talk between VEGF and CCR3 signaling. VEGF
and CCR3 signaling are both important in human neovascular
AMD.2,9 We previously found that RPE-produced VEGF trig-
gered VEGFR2 signaling and active Rac1 in CECs that caused
CEC transmigration of the RPE.14,15 We showed that CCL11-
stimulated CCR3 signaling also stimulates Rac1 activation and
CEC chemotactic migration. In this study, we now report
several lines of evidence that cross-talk exists between the
CCR3 and VEGF signaling pathways. First, we found a physical
interaction between CCR3 and VEGFR2 through coimmuno-
precipitation of CCR3 and VEGFR2 in response to stimulation
with ligands CCL11 and VEGF. Chemokines and their receptors
usually function in complex networks involving homo- and
heterodimerization with other chemokine receptors or recep-
tor tyrosine kinases (RTKs),29 and our coimmunoprecipitation
results suggest this as a possibility between VEGFR2 and CCR3.
We also found that CCL11 treatment activated VEGFR2, recog-
nized as increased phosphorylation of VEGFR2. GPCRs can
interact with other receptors through transactivation of recep-
tors, including RTKs,29 such as VEGFR2. The data in our report
suggest that CCL11 may be able to act on VEGFR2 via CCR3.
Our data also showed a synergistic effect of the interaction
FIGURE 6. Ligand-activated CCR3 coimmunoprecipitates with and activates VEGFR2 and leads to synergistic
activation of Rac1. (A) Coimmunoprecipitation of CCR3 and VEGFR2 was performed in CECs incubated with
VEGF (20 ng/mL) and CCL1 (10 ng/mL) for 1 hour using antibodies to CCR3 and blotting for VEGFR2 (n  3).
(B) Phospho-VEGFR2 was detected by immunoprecipitation with antibodies against VEGFR2 and a blot for
phospho-tyrosine in CECs treated with CCL11 (10 ng/mL) for 0, 15, 30, and 60 minutes; phosphorylation of
VEGFR2 in CECs exposed to VEGF (20 ng/mL) for 15 minutes was a positive control. Overall one-way ANOVA
P  0.0001; post-hoc Newman-Keuls multiple comparison testing: *P  0.05, **P  0.01, and ***P  0.001 vs.
0 minutes of CCL11 treatment (n  3). (C) Rac1 activity in CECs was measured in response to the stimulation
of CCL11 (10 ng/mL) and VEGF (20 ng/mL). Rac1 activity in cells with either CCL11 or VEGF treatment alone
was used as a control. Overall one-way ANOVA P  0.0001; post-hoc Newman-Keuls multiple compar-
ison testing: **P  0.01 and ***P  0.001 vs. control; #P  0.05 vs. CCL11 alone; $P  0.05 vs. VEGF
alone (n  3).
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between activated CCR3 and VEGFR2 on downstream activa-
tion of Rac1, which is important in CEC transmigration of the
RPE.12–14
In summary, we have shown that increased age and stresses
associated with AMD, such as oxidative stress, lead to in-
creased expression of CCR3 in CECs and its ligands in RPE.
CCR3 by itself is able to mediate CEC migration, and it can also
modulate VEGFR2 signaling and exacerbate Rac1 activation.
The cross-talk of CCR3 with VEGF signaling suggests that
inhibition of CCR3 may be an additional method to prevent or
treat vision-threatening neovascular AMD. However, in sec-
tions from aged human eyes, we found CCR3 labeling occurred
in other retinal neurons. This could indicate that inhibiting
CCR3 may be detrimental to retinal survival. Rac1-mediated
NADPH oxidase activation can generate ROS and cytokines,
which have been reported to also cause retinal neuronal dam-
age.30 Therefore, inhibition of CCR3-induced Rac1 activation
may alternatively promote neuronal survival. In future studies,
we will look at other mechanisms of cross-talk and also poten-
tial downstream signaling through pathways, such as ERK
(extracellular signal-regulated kinase),31 found activated by
CCR3 signaling in other diseases.
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